Navigation Links
GOLFIG increased progression-free survival in colorectal cancer patients
Date:4/6/2011

ORLANDO, Fla. Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

Patients with advanced colorectal cancer are typically treated with combination chemotherapy with fluorouracil or the derivative product, capecitabine with or without levofolinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) given alone, or with the monoclonal antibodies bevacizumab, cetuximab or panitumumab.

"These combinations have been successful in inducing tumor regression, retarding disease progression and increasing overall survival. However, the average progression-free survival and overall survival are still no more than eight to 10 months and 20 to 22 months, respectively," said Pierpaolo Correale, M.D., Ph.D., an oncologist at the Siena University School of Medicine in Italy.

This study was started in 2005, before monoclonal antibodies were routinely used. Correale and colleagues added gemcitabine to FOLFOX followed by granulocyte-macrophage colony stimulating factor and low-dose aldesleukine (GOLFIG) to boost the immune system in an effort to fight cancer.

The researchers randomized 130 patients to receive GOLFIG or FOLFOX for a maximum of 12 cycles and then receive maintenance treatment until disease progression. The study was designed to follow the patients in both arms until death, but was ended early due to significantly better results seen with the GOLFIG regimen.

So far, the patients who received GOLFIG had a progression-free survival of 16.5 months compared with the 7.5 months recorded in those patients who received FOLFOX.

"Based on our experience and results to date, we believe that the GOLFIG regimen is superior to FOLFOX chemotherapy in terms of efficacy and comparable in terms of toxicity and cost," said Correale. "We were very surprised to find such a significant difference in terms of overall survival with this low number of patients."

The challenge for the future will be to compare GOLFIG regimen with regimens containing monoclonal antibodies, he said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Mayo: Variants in gene on X chromosome associated with increased susceptibility to Alzheimers
2. Reproductive life of male mice is increased by living with females
3. Swimmers at public beaches show increased risk of exposure to contagious staph bacteria
4. How increased UV exposure impacts plants
5. Mothers of multiple births at increased odds of postpartum depression
6. Vitamin D deficiency related to increased inflammation in healthy women
7. Purple sweet potato means increased amount of anti-cancer components
8. Severe breathing disorders during sleep are associated with an increased risk of dying
9. Increased climate volatility expected to worsen poverty vulnerability in developing countries
10. Insufficient levels of vitamin D puts elderly at increased risk of dying from heart disease
11. Global warming may spur increased growth in Pacific Northwest forests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology , ... recognition technologies, today announced that the MegaMatcher On ... was submitted for the NIST Minutiae Interoperability ... all the mandatory steps of the evaluation protocol. ... a continuing test of fingerprint templates used to ...
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... San Antonio Texas (PRWEB) , ... ... ... announced today that it will share findings demonstrating the value of DNA ... cancer patients at this year’s San Antonio Breast Cancer Symposium. Using molecular ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical ... FDA Class II 510(k) clearance for their flagship medical device, SimplECG. , With ... monitoring devices that rely on cloth-based nanosensors. While other companies have attempted to ...
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
Breaking Biology Technology: